Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Acute agitation is common amongst individuals with bipolar disorder and schizophrenia and represents a medical emergency. Commonly used medications for agitation, such as benzodiazepines and antipsychotics, are often delivered intramuscularly and may cause adverse effects. Non-invasive, effective, and safe alternative treatment options are needed. The purpose of this review article is to describe the efficacy and safety of sublingual formulation of dexmedetomidine (Igalmi), a selective α2-adrenergic receptor agonist, U.S. Food and Drug Administration approved for the treatment of acute agitation in adults with schizophrenia or bipolar I and II disorder. In two phase 3 trials, two dose strengths of sublingual dexmedetomidine 180 μg and 120 μg were safe and effective in managing acute agitation in patients with bipolar disorder or schizophrenia. Both doses significantly reduced Positive and Negative Syndrome Scale-Exited Component scores two hours after receiving a single dose as compared to placebo, indicating a substantial improvement in agitation. The beneficial effects of sublingual dexmedetomidine were achieved without serious adverse events with the most common side effect being mild somnolence. The clinical trial data suggest that sublingual dexmedetomidine represents a safe and effective treatment option in the armamentarium for acute agitation for people with schizophrenia or bipolar disorder.
Abstract
Acute agitation is common amongst individuals with bipolar disorder and schizophrenia and represents a medical emergency. Commonly used medications for agitation, such as benzodiazepines and antipsychotics, are often delivered intramuscularly and may cause adverse effects. Non-invasive, effective, and safe alternative treatment options are needed. The purpose of this review article is to describe the efficacy and safety of sublingual formulation of dexmedetomidine (Igalmi), a selective α2-adrenergic receptor agonist, U.S. Food and Drug Administration approved for the treatment of acute agitation in adults with schizophrenia or bipolar I and II disorder. In two phase 3 trials, two dose strengths of sublingual dexmedetomidine 180 μg and 120 μg were safe and effective in managing acute agitation in patients with bipolar disorder or schizophrenia. Both doses significantly reduced Positive and Negative Syndrome Scale-Exited Component scores two hours after receiving a single dose as compared to placebo, indicating a substantial improvement in agitation. The beneficial effects of sublingual dexmedetomidine were achieved without serious adverse events with the most common side effect being mild somnolence. The clinical trial data suggest that sublingual dexmedetomidine represents a safe and effective treatment option in the armamentarium for acute agitation for people with schizophrenia or bipolar disorder.
참고문헌 (30)
- San L, "State of acute agitation at psychiatric emergencies in Europe : the STAGE study", Clin Pract Epidemiol Ment Health, 12, pp.75~86 (2016)
- Holloman GH Jr, "Overview of project BETA : best practices in evaluation and treatment of agitation", West J Emerg Med, 13, pp.1~2 (2012)
- Hazlett SB, "Epidemiology of adult psychiatric visits to US emergency departments", Acad Emerg Med, 11, pp.193~195 (2004)
- Sankaranarayanan J, "Epidemiology and characteristics of emergency departments visits by US adults with psychiatric disorder and antipsychotic mention from 2000 to 2004", Curr Med Res Opin, 23, pp.1375~1385 (2007)
- Allen MH, "The expert consensus guideline series. Treatment of behavioral emergencies 2005", J Psychiatr Pract, 11(Suppl 1), pp.5~108 (2005)
- Garriga M, "Assessment and management of agitation in psychiatry : expert consensus", World J Biol Psychiatry, 17, pp.86~128 (2016)
- Raveesh BN, "Assessment and management of agitation in consultation-liaison psychiatry", Indian J Psychiatry, 64(Suppl 2), pp.S484~S498 (2022)
- Roppolo LP, "Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA(best practices in the evaluation and treatment of agitation)", J Am Coll Emerg Physicians Open, 1, pp.898~907 (2020)
- Wilson MP, "The psychopharmacology of agitation : consensus statement of the American Association for Emergency Psychiatry project beta psychopharmacology workgroup", West J Emerg Med, 13, pp.26~34 (2012)
- Wood B, "Clinically significant acute agitation : consensus update", US Pharm, 35, pp.HS-9~HS-15 (2010)
- Lin J, "Efficacy of ketamine for initial control of acute agitation in the emergency department : a randomized study", Am J Emerg Med, 44, pp.306~311 (2021)
- Miller J, "Managing acute agitation and aggression in the world of drug shortages", Ment Health Clin, 11, pp.334~346 (2021)
- "IGALMITM (dexmedetomidine) sublingual film, for sublingual or buccal use" (2022)[URL]
- Preskorn SH, "How an understanding of the function of the locus coeruleus led to use of dexmedetomidine to treat agitation in bipolar disorder : example of rational development of psychiatric medications", J Psychiatr Pract, 28, pp.227~233 (2022)
- Preskorn SH, "Effect of sublingual dexmedetomidine vs placebo on acute agitation associated with bipolar disorder : a randomized clinical trial", JAMA, 327, pp.727~736 (2022)
- Citrome L, "Sublingual dexmedetomidine for the treatment of acute agitation in adults with schizophrenia or schizoaffective disorder : a randomized placebo-controlled trial", J Clin Psychiatry, 83, pp.22~ (2022)
- Citrome L, "Sublingual dexmedetomidine for agitation associated with schizophrenia or bipolar disorder : a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed", Adv Ther, 39, pp.4821~4835 (2022)
- "ADASUVETM (loxapine) inhalation powder, for oral inhalation use" (2012)[URL]
- Dundar Y, "Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder : a systematic review and meta-analysis", Hum Psychopharmacol, 31, pp.268~285 (2016)
- Zeller SL, "Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting", West J Emerg Med, 17, pp.165~172 (2016)
- Day JC, "Attitudes toward antipsychotic medication : the impact of clinical variables and relationships with health professionals", Arch Gen Psychiatry, 62, pp.717~724 (2005)
- Zareifopoulos N, "Treatment options for acute agitation in psychiatric patients : theoretical and empirical evidence", Cureus, 11, pp.e6152~ (2019)
- Townsend M, "Antipsychotic-related stigma and the impact on treatment choices : a systematic review and framework synthesis", Patient Prefer Adherence, 16, pp.373~401 (2022)
- "Precedex (dexmedetomidine hydrochloride) label" (2013)[URL]
- Nelson S, "Defining the role of dexmedetomidine in the prevention of delirium in the intensive care unit", Biomed Res Int, 2015, pp.635737~ (2015)
- Muzyk AJ, "Role of α2-agonists in the treatment of acute alcohol withdrawal", Ann Pharmacother, 45, pp.649~657 (2011)
- Muzyk AJ, "The use of dexmedetomidine in alcohol withdrawal", J Neuropsychiatry Clin Neurosci, 24, pp.E45~E46 (2012)
- Almeida M, "Treatment of acute agitation associated with excited catatonia using dexmedetomidine : case series and literature review", Prim Care Companion CNS Disord, 23, pp.20~ (2021)
- Hsiao JK, "Sublingual dexmedetomidine as a potential new treatment for agitation", JAMA, 327, pp.723~725 (2022)
- "Dexmedetomidine sublingual film (Igalmi) for acute agitation", Med Lett Drugs Ther, 64, pp.203~205 (2022)